Testing Bhanga (Cannabis) Powder Before Surgery in Mouth Cancer Patients Phase 1 Study

Phase 1 study of safety and feasibility of Bhanga (Cannabis sativa) churna in the Pre-operative period in oral cavity squamous cell cancer. - NIL

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/106030

Enrollment

Registered

2026-03-12

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C060- Malignant neoplasm of cheek mucosa

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Histo-pathologically proven patients of oral cavity SCC. Only clearly operable cancers planned to undergo upfront curative surgery. Patient fit for surgery (ASA Grade I / II). Patient voluntarily willing to give consent for study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
1.The study will generate hypotheses for future investigation of Bhanga churna in the preoperative period to achieve improved clinical outcomes of OCSCCTimepoint: Baseline Day 21 Day 49	—

Secondary

Measure	Time frame
2. Pharmacokinetic modelling Timepoint: Day 1 Predose 30 min 1Hour 1.5 Hour 2 Hour 4 Hour 6 Hour Day 21 Predose 30 min 1Hour 1.5Hour 2 Hour 4 Hour 6 Hour Before Surgery At the end of surgery Post-operative Day 01 Post-operative Day 02 Post-operative Day 03 Post-operative Day 14 ;Transcriptomic AnalysisTimepoint: Day 1 (Before dose intake) Day 22 (On the day of surgery) Before Surgery During Surgery At the end of Surgery	—

Measure

Time frame

2. Pharmacokinetic modelling Timepoint: Day 1 Predose 30 min 1Hour 1.5 Hour 2 Hour 4 Hour 6 Hour Day 21 Predose 30 min 1Hour 1.5Hour 2 Hour 4 Hour 6 Hour Before Surgery At the end of surgery Post-operative Day 01 Post-operative Day 02 Post-operative Day 03 Post-operative Day 14 ;Transcriptomic AnalysisTimepoint: Day 1 (Before dose intake) Day 22 (On the day of surgery) Before Surgery During Surgery At the end of Surgery

—

Countries

India

Contacts

Public ContactDr Vikram Gota

Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)

vikramgota@gmail.com02227405493

Outcome results